CD8A and cancer: In conclusion, our data demonstrate that effective priming of ErbB2-specific CD8+ T cells occurred upon in vivo application of cancer vaccines consisting of an ErbB2-derived Tc-epitope attached to a liposomal carrier via an adjuvant Pam3CSS lipopeptide anchor.